<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01238328</url>
  </required_header>
  <id_info>
    <org_study_id>HORCSCT-0906</org_study_id>
    <nct_id>NCT01238328</nct_id>
  </id_info>
  <brief_title>Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis</brief_title>
  <official_title>Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and side effects of donor
      hematopoietic cells using chemotherapy regimen without total-body irradiation in children
      undergoing a hematopoietic stem cell transplant for Mucopolysaccharidosis. The blood stem
      cells will be derived from either related donor or unrelated umbilical cord blood or
      haploidentical donor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Overall Survival and Progressive Free Survival in patient with Mucopolysaccharidosis who receive allogeneic Hematopoietic stem cell transplantation (HSCT)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>One year overall survival after allogeneic hematopoietic stem cell transplantation (HSCT)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One year Progressive Free Survival after allogeneic hematopoietic stem cell transplantation (HSCT)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplantation Related Mortality (TRM) after allogeneic hematopoietic stem cell transplantation (HSCT)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic Graft-versus-host disease (GVHD) rate after allogeneic hematopoietic stem cell transplantation (HSCT)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Mucopolysaccharidosis</condition>
  <arm_group>
    <arm_group_label>Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conditioning regimen</intervention_name>
    <description>For sibling full match:
Busulfan 16 mg/kg &gt;5year - 20 mg/kg &lt;5year po
Cyclophosphamide 200 mg/kg iv
For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:
Busulfan 16 mg/kg &gt;5year - 20 mg/kg &lt;5year po
Cyclophosphamide 200 mg/kg iv
Antithymocyte globulin (ATG) rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg
For haploidentical:
Busulfan 16 mg/kg &gt;5year - 20 mg/kg &lt;5year po
Cyclophosphamide 200 mg/kg iv
Fludarabine 160 mg/m^2</description>
    <arm_group_label>Transplantation</arm_group_label>
    <other_name>Endoxan</other_name>
    <other_name>Antithymocyte globulin (ATG) rabbit : Thymoglobulin</other_name>
    <other_name>Antithymocyte globulin (ATG) horse : Atgam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Graft-versus-host disease (GVHD) prophylaxis</intervention_name>
    <description>Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in peripheral blood stem cell transplant (PBSCT) and +11 in Bone marrow transplantation or Umbilical Cord Blood (UCB) transplantation) then 9 mg/kg/day po
10 mg/m^2 iv day +1 then 6 mg/m^ iv day +3 and +6 (Not for UCBT)</description>
    <arm_group_label>Transplantation</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplantation</intervention_name>
    <description>Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:
Sibling full match
Other related full match
Sibling or other related with 1 mismatch antigen
Cord Blood
Haploidentical</description>
    <arm_group_label>Transplantation</arm_group_label>
    <other_name>HSCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Mucopolysaccharidosis type 1, 6 and 7 confirm by leukocyte enzyme assay

          -  Age up to 8 year old

          -  Have suitable donor

        Exclusion Criteria:

          -  Creatinine clearance ≤ 40ml/min/1.73m^2

          -  Bilirubin ≥ 3mg/dL

          -  SGPT ≥ 500 U/L

          -  Current severe infection

          -  Evidence of CNS involvement

          -  Morbidity such as blindness or deafness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amir Ali Hamidieh, MD</last_name>
    <phone>84902645</phone>
    <phone_ext>+98 21</phone_ext>
    <email>aahamidieh@sina.tums.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematology-Oncology &amp; SCT Research Center</name>
      <address>
        <city>Teharn</city>
        <state>Tehran</state>
        <zip>14114</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Ali Hamidieh, MD</last_name>
      <phone>84902645</phone>
      <phone_ext>+9821</phone_ext>
      <email>aahamidieh@sina.tums.ac.ir</email>
    </contact>
    <investigator>
      <last_name>Amir Ali Hmidieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ardeshir Ghavamzadeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kamran Alimoghaddam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahdi Jalili, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://horcsct.tums.ac.ir</url>
    <description>Hematology-Oncology and Stem Cell Transplantation Research Center</description>
  </link>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>July 25, 2011</lastchanged_date>
  <firstreceived_date>November 8, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Mahdi Jalili MD / Hematology-Oncology and SCT Research Center</name_title>
    <organization>Tehran University of Medical Sciences</organization>
  </responsible_party>
  <keyword>Mucopolysaccharidosis</keyword>
  <keyword>HSCT</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
</clinical_study>
